Biotechnology veteran — and MSSEF board member — Michael S. Wyzga has assumed the position of CEO at Cambridge, MA-based Radius Health, following a 13-year career at Genzyme. While serving as Genzyme’s Executive Vice President, Finance, and CFO, Mike led the $20.1 billion sale of Genzyme to Sanofi last April — the second-largest acquisition ever in the industry.
In his new role at Radius, Mike will drive corporate strategy and lead the advancement of Phase 3 osteoporosis drug BA058. “It is a great privilege to have been asked to lead Radius at this important point in the company’s evolution,” Mike said. “BA058 represents a unique opportunity to advance not just a best-in-class drug, but potentially a best-in-disease drug in the expanding osteoporosis market. BA058 has the potential to transform the treatment of osteoporosis and optimize outcomes based not only on its unique bone-building and safety attributes but on the development of the once-daily, short wear-time transdermal patch, our fast follow-on product that we believe will further expand the appeal and market penetration for our product.”